GSTM1 and anemia (phenotype): In the FIND CKD trial, IV ferric calboxymaltose targeting higher iron parameter levels (achieved ferritin = 503 ng/mL; TSAT = 31.2%) resulted in greater Hb levels, reducing or delaying the need for anemia medications (ESAs or blood transfusions) other than oral iron21.